Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta by Philip E Castle et al.
RESEARCH ARTICLE Open Access
Human papillomavirus genotypes detected in
clinician-collected and self-collected specimens
from women living in the Mississippi Delta
Philip E Castle1*, Julia C Gage2, Edward E Partridge3, Alfio Rausa4, Patti E Gravitt5 and Isabel C Scarinci3
Abstract
Background: There are no data available on human papillomavirus (HPV) infections in women living in the
Mississippi Delta, where cervical cancer incidence and mortality among African American women is among the
highest in the United States. The aim of this analysis was to report the age-specific prevalence of HPV in this
population.
Methods: We recruited 443 women, 26–65 years of age, from the general population of women living in the
Mississippi Delta to participate; 252 women had been screened for cervical cancer within the last 3 years while 191
had not. Women underwent a pelvic exam and had clinician-collected Pap sample taken for the routine cervical
cancer screening by cytology. Women were asked to collect a self-collected specimen at home and return it to the
clinic. Both specimens were tested for HPV genotypes.
Results: Four hundred and six women (91.6%) had HPV genotyping results for the clinician-collected and
self-collected specimens. The prevalence of carcinogenic HPV was 18.0% (95% CI: 14.4%-22.1%) for
clinician-collected specimens and 26.8% (95% CI: 22.6%-31.4%) for self-collected specimens. The concordance for
the detection of carcinogenic HPV between clinician-collected and self-collected specimens was only fair (kappa =
0.54). While the prevalence of carcinogenic HPV in either sample decreased sharply with increasing age (ptrend<
0.01), the prevalence of non-carcinogenic HPV did not, especially the prevalence of HPV genotypes in the alpha 3/
4/15 phylogenetic group.
Conclusions: The prevalence of carcinogenic HPV in our sample of women living in the Mississippi Delta was
greater than the prevalence reported in several other U.S. studies. The high carriage of HPV infection, along with
lack of participation in cervical cancer screening by some women, may contribute to the high cervical cancer
burden in the region.
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Background
Persistent cervical HPV infection by cancer-associated
or carcinogenic HPV is the necessary cause of cervical
cancer [1,2]. DNA testing for HPV is more sensitive but
less specific for detection of precancerous lesions and
early cancer than cervical cytology [3-5]. HPV DNA test-
ing of self-collected specimens is equally sensitive as cy-
tology [6] and could be used to reach populations not
being screened by current programs [7-15].
The Mississippi Delta is a little studied population that
has historically had several-fold higher annual rates of
cervical cancer incidence and mortality than those for
the general U.S. [16,17]. The overarching goal of our
study in the Mississippi Delta was to study the accept-
ability of self-collection and HPV testing as an alterna-
tive to Pap testing. We previously reported that under-
screened women were almost twice as likely to choose
self-collection over free Pap testing, and twice as many
of those who chose self-collection completed their
screening compared those who chose free Pap testing
[18]. The goal of this specific analysis was examine the
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impact of age and anatomic site of specimen collection
on the prevalence of HPV, as a proxy for specificity. We
wanted to understand the potential impact of using self-
collection and HPV DNA testing on the patient.
Methods
Recruitment and clinical methods were detailed previ-
ously [19]. Briefly, women undergoing routine screening
(n = 252)(“screened”) or had not been screened in the
last three years (n = 191) (“under-screened”) were
recruited as part of a larger study of self-collection and
HPV DNA testing in 4 counties (Tallahatchie, Leflore,
Sunflower, and Washington) located in northwest
Mississippi and part of the Mississippi Delta. Women
aged 26 to 65 years of age, non-pregnant, with a cervix,
and willing to provide written, informed consent were
enrolled into the study. Institutional review boards from
the NCI, UAB, State of Mississippi Health Department,
and Westat approved this study.
For all participants, cervical specimens were collected
into PreservCyt (Hologic, Bedford, MA, USA) for rou-
tine cervical cytology and the residual was retained for
HPV testing. Women were given a kit for self-collection




&OS=PN/6,475,165&RS=PN/6,475,165) and a vial of
Scope™ (Proctor and Gamble, Cincinnati, OH, USA)
mouthwash for specimen transport [22]. The self-
collection device physically and mechanically resem-
bles a tampon and includes an outer sheath to shield
the collection from vaginal contamination and irrele-
vant vaginal HPV infections. Women were instructed
to insert the device into their anterior vagina, expose
the Dacron collection tip to obtain a sample of cervical
cells, retract the tip into the sheath, remove the device,
and eject the tip into the transport medium. We used
mouthwash as our transport medium to avoid giving
kits containing toxic liquid-based cytology medium to
our participants to take home [22].
Specimens were tested for 37 HPV genotypes (6, 11,
16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51–56, 58, 59, 61,
62, 64, 66–73, 81–84, 82v, and 89) using Linear Array
(LA; Roche Molecular Systems, Pleasanton, CA, USA)
[23,24]. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68 were classified as the certain or probable carcino-
genic HPV genotypes [25]. HPV genotypes were also
classified according to broad branches in the phylogen-
etic tree for HPV genotypes [26,27]: 1) HPV genotypes 6,
11, 40, and 42, which are classified in the alpha 1, 8, and
10 group (alpha 1/8/10 genotypes). HPV 6 and 11 cause
90% of condyloma accuminata (genital warts); 2) HPV
genotypes 16, 18, 26, 31, 33, 35, 39, 45, 51–56, 58, 59,
64, 66, 67, 68, 69, 70, 73, 82, and 82v, which are classi-
fied in the alpha 5, 6, 7, 9, and 11 group (alpha 5/6/7/9/
11 genotypes). All the carcinogenic and borderline car-
cinogenic HPV genotypes are found in these species; and
3) HPV genotypes 61, 62, 71, 72, 81, 83, 84, and 89,
which are classified in the alpha 3, 4, and 15 group
(alpha 3/4/15 genotypes). There is some evidence that
these HPV genotypes in these species have a predilection
for vaginal tissue [28-31].
Logistic regression was used to calculate odds ratios
(OR), 95% confidence intervals, and p values to test for
differences between study groups (screened vs. under-
screened) and linear trends with age groups (26–39, 30–
39, 40–49, and 50–65 years) for testing HPV positive for
categories of HPV. For categories of HPV prevalences,
both crude and adjusted for study group and age group,
were calculated. Binomial exact 95% confidence intervals
were used where noted. An exact version of McNemar
chi-square test or a symmetry chi-square test was used
to test for differences in prevalence for individual or spe-
cific group of HPV genotypes from the same specimen
or for same individual or specific group of HPV geno-
types from different specimens.
A post-hoc power calculation based on a McNemar
chi-square test indicated that 1) a sample size of 406
pairs for the whole analysis population achieves 80%
power (alpha = 0.05) to detect a difference in prevalence
of 4.5% between specimens collections if the discordance
was 10%, of 6.4% if the discordance was 20%, and of
7.8% if the discordance was 30%, and 2) a sample size of
312 pairs for women 30 years and older achieves 80%
power (alpha = 0.05) to detect a difference in prevalence
of 5.2% between specimens collections if the discordance
was 10%, of 7.3% if the discordance was 20%, and 8.9% if
the discordance was 30%.
A p value of < 0.05 was considered statistically signifi-
cant. STATA Version 11.1 was used for these analyses
(StataCorp, College Station, Texas, USA).
Results
There were HPV testing results available for 440 (99.7%)
clinician-collected specimens and 409 (92.3%) self-
collected specimens. The analyses were restricted to the
406 (91.6%) women for whom both results were avail-
able, which included 231 screened women and 175
under-screened women. Of the 406 subjects included in
this analysis, 370 (91.1%) identified themselves as Black/
African American, 33 (8.1%) as White/Caucasian, and 3
(0.7%) as other. The mean and median ages were
37.5 years and 36 years, respectively.
We used logistic regression to show the impact of the
two study groups and age on detection of HPV. As
shown in Table 1, there was no significant difference in
the HPV detection between study populations for
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categories of any HPV, carcinogenic HPV, non-
carcinogenic HPV, and three phylogenetically defined
categories of alpha 1/8/10, alpha 5/6/7/9/11, and alpha
3/4/15 HPV genotypes between populations for
clinician-collected specimens or for self-collected speci-
mens. We noted that in general the under-screened
population had more HPV, albeit not significantly so;
underscreened women were non-significantly more
likely to have alpha 1/8/10 genotypes compared to
screened women (OR = 1.9, 95% CI: 0.74-4.7). Because
there was no evidence of significant differences in the
prevalence of HPV between the screened and under-
screened groups, the two were combined henceforth.
Increasing age was statistically associated with a lower
likelihood of testing positive of any HPV, carcinogenic
HPV, and alpha 5/6/7/9/11 genotypes, but not for alpha
3/4/15 genotypes, for both specimen types (Table 1).
We calculated the prevalence of HPV categories by
collection method, and the concordance between speci-
mens, as shown in Table 2; prevalence adjusted for age
group and the population group (screened vs. under-
screened) was not appreciably different (data not
shown). The prevalence of any HPV was 42.4% (95% CI:
37.5%-47.3%) for clinician-collected specimens and
54.7% (95% CI: 49.7%-59.6%) for self-collected speci-
mens; the discordance (disagreement) was 27% and
therefore the post-hoc power was 99.7%. The adjusted
prevalence of carcinogenic HPV was 18.0% (95% CI:
14.4%-22.1%) for clinician-collected specimens and
26.8% (95% CI: 22.6%-31.4%) for self-collected speci-
mens. Self-collected specimens were more likely to test
positive for any HPV, carcinogenic HPV, non-
carcinogenic HPV, alpha 5/6/7/9/11, and alpha 3/4/15
genotypes than clinician-collected specimens (p < 0.001).
As a consequence of the differences in HPV detection
by specimen type, the concordance between the two spe-
cimens for HPV detection in any HPV category was only
fair, with kappa values around 0.50.
The prevalence of carcinogenic HPV for women 30
and older (n = 312), the ages at which HPV and cytology
cotesting is acceptable by national screening guidelines
[32-34], was 14.4% (95% CI: 10.7%-18.8%) for clinician-
collected specimens and 24.0% (95% CI: 19.4%-29.2%)
for self-collected specimens, the latter of which was sig-
nificantly greater than the former (p < 0.001). The dis-
cordance (disagreement) was 17% and therefore the
post-hoc power was 98.7%.
The concordance for HPV detection, categorizing hier-
archically according to cancer risk, for the two speci-
mens is shown in Table 3. The crude kappa was 0.47
and the percentage agreement was 66%. There was a sig-
nificant difference in detection of HPV classified in this
manner (p = 0.0002), primarily because the following dis-
cordant (self-collected/clinician-collected) results were
common: 1) non-carcinogenic HPV/HPV negative; 2) car-
cinogenic HPV/HPV negative; and 3) carcinogenic HPV/
non-carcinogenic HPV.
The agreement statistics for detection of all 37 HPV
genotypes individually in self-collected vs. clinician-
collected specimens were a kappa value of 0.56 (95% CI:
0.52-0.61), the total agreement of 97.8%, and the positive
agreement of 40.0%, with self-collected specimens more
likely to test positive for any of the HPV genotypes than
clinician-collected specimens (p < 0.0001). The preva-
lence for individual HPV genotypes is shown in the
Additional file 1: Table S1. The 5 most common HPV
genotypes found in clinician-collected specimens were
HPV54 (4.9%), HPV62 (4.7%), HPV83 (4.4%), HPV52
(3.9%), and HPV71 (3.4%); prevalences of HPV16 and
HPV18, the two genotypes targeted by the current gen-
eration of HPV vaccines were 2.5% and 1.5%, respect-
ively. The 5 most common HPV genotypes found in self-
collected specimens were HPV54 (8.1%), HPV83 (7.9%),
HPV70 (7.4%), HPV62 (7.4%), and HPV81 (6.4%); the
prevalences of HPV16 and HPV18, the two genotypes
targeted by the current generation of HPV vaccines were
3.0% and 3.9%, respectively. Individually, HPV18, 33, 54,
55, 62, 68, 70, 81, 83, and 84 were more commonly
detected (p < 0.05) in self-collected specimens than
clinician-collected specimens.
Table 1 Results of logistic regression models to examine the relationship of study population and age on detection of
HPV groups
Clinician collected Self-collected
OR p 95% CI ptrend OR p 95% CI ptrend
Any HPV 1.2 0.4 0.77-1.8 0.01 1.0 0.9 0.68-1.6 0.03
Carcinogenic 1.1 0.6 0.66-2.0 <0.001 1.4 0.1 0.90-2.3 0.004
Non-Carcinogenic 1.1 0.7 0.69-1.8 0.8 0.73 0.2 0.46-1.2 0.7
alpha 1/8/10 1.4 0.6 0.44-4.5 0.5 1.9 0.2 0.74-4.7 0.8
alpha 5/6/7/9/11 0.94 0.8 0.59-4.5 0.003 1.1 0.6 0.74-1.7 0.01
alpha 3/4/15 1.1 0.8 0.64-1.8 0.4 0.79 0.3 0.51-1.2 0.7
Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated as a measure of association of women not having been screened in the last 3 years (vs.
the reference of those who had) with HPV detection; p value was included for reference. Age groups were modeled continuously to assess the age trend (ptrend).
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Shown in Figure 1 are the age group-specific patterns of
prevalences for any HPV, any carcinogenic HPV, alpha 5/6/
7/9/11 genotypes, and any alpha 3/4/15 genotypes for the
two groups combined. While the prevalence of carcino-
genic HPV detected in clinician-collected (ptrend = 0.0002)
and self-collected (ptrend = 0.009) specimens decreased with
increasing age, the prevalence of non-carcinogenic HPV
did not (ptrend = 0.3 for clinician-collected, ptrend = 0.08 for
self-collected). Grouping of HPV genotypes based on
branches in the phylogenetic tree highlighted these
differences in age trends. While the prevalence of alpha 5/
6/7/9/11 detected in clinician-collected (ptrend = 0.001) and
self-collected (ptrend = 0.007) decreased with increasing age,
the prevalence of alpha 3/4/15 did not (ptrend = 0.4 for clin-
ician-collected, ptrend = 0.4 for self-collected).
Discussion
We found the prevalence of carcinogenic HPV to be
relatively high in this population compared to other U.S.
populations. The prevalence of carcinogenic HPV in
clinician-collected specimens from women 30 and older
in this population was approximately 2-fold higher than
what has been observed at Kaiser Permanente Northern
California (6.5% in women 30 and older) [35], and 40%
higher in both a study that included women attending
sexually transmitted infection (STI) clinics (~10% in
women 30 and older) [36] and in a state-wide population
study of women living in New Mexico (~10% in women
31 and older) [37], a state that ranks along with Missis-
sippi as one of the poorest states in the US. The high
prevalence of carcinogenic HPV reported in this study
Table 2 Prevalence of HPV groups in clinician- and self-collected specimens (n = 406)
Prevalence Concordance
Clinician-collected Self-collected % Positive
agreementPrevalence 95% CI Prevalence 95% CI % Agreement Kappa p
Any HPV 42.4% 37.5%-47.3% 54.7% 49.7%-59.6% 73% 57% 0.48 <0.001
Carcinogenic 18.0% 14.4%-22.1% 26.8% 22.6%-31.4% 84% 47% 0.54 <0.001
Non-Carcinogenic 31.8% 27.3%-36.5% 44.6% 39.7%-49.6% 75% 53% 0.49 <0.001
alpha 1/8/10 3.2% 1.7%-5.4% 5.2% 3.2%-7.8% 97% 42% 0.57 0.06
alpha 5/6/9/11 28.8% 24.5%-33.% 41.4% 36.5%-46.4% 77% 51% 0.51 <0.001
alpha 3/4/15 21.2% 17.3%-25.5% 31.8% 27.3%-36.5% 82% 48% 0.53 <0.001
Differences in prevalence detected in clinician- and self-collected specimens were tested for statistical differences using an exact version of McNemar’s chi-square
test. P value of less than 0.05 is considered significant and indicated by bolded font.
Table 3 A comparison of detection of human papillomavirus (HPV) genotypes, classified hierarchically according to
cancer risk (HPV16>HPV18>other carcinogenic HPV>non-carcinogenic HPV>HPV negative), for clinician-collected and
self-collected specimens from women living in the Mississippi Delta
Self collected
HPV16 HPV18 Other Carc. Non Carc. HPV Negative Total
Clinician Collected
HPV Negative n 5 5 23 46 155 234
% cell 1.2% 1.2% 5.7% 11.3% 38.2
Non Carcinogenic n 2 3 13 62 19 99
% cell 0.5% 0.7% 3.2% 15.3% 4.7%
Other Carcinogenic n 1 2 44 4 7 58
% cell 0% 1% 11% 1% 2%
HPV18 n 0 3 1 0 1 5
% cell 0.% 0.7% 0.2% 0.0% 0.2%
HPV16 n 4 1 2 1 2 10
% cell 1.0% 0.2% 0.5% 0.2% 0.5%
Total 12 14 83 113 184 406
The number (n) and cell percentage (% cell) for each pairwise results is shown. The crude kappa was 0.47, percent agreement was 66%, and symmetry chi-square
was p = 0.0002. Abbreviation: carc., carcinogenic.
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was not due to the use of LA for HPV detection as the
prevalence of HPV was similar using Hybrid Capture 2
(p = 0.9) [19] the test used in these other reports in two
of the aforementioned studies (35;36). We speculate that
the higher prevalence of carcinogenic HPV, which has
been shown to correlate with cervical cancer incidence
[38], and a lack of screening in a subset of women living
in the Mississippi Delta may in part account for the
higher annual rate of cervical cancer incidence in this re-
gion compared to other places in the U.S. [16].
We note that this study was only cross-sectional and
therefore could not assess the total lifetime exposure to
HPV, nor could we measure HPV persistence, which
precedes and predicts the development of cervical pre-
cancerous lesions [39]. Yet HPV prevalence has been
correlated with the risk of cervical cancer [38], support-
ing the possibility that that this population of women
living in the Mississippi Delta are at a higher risk than
the general U.S. population.
The prevalence of HPV and the HPV genotypes
detected was strongly influenced by both the age of the
patient and the type of sampling (clinician vs. self ). The
higher prevalence of carcinogenic HPV in women under
30 (vs. 30 and older) suggests may preclude the use of
self-collection and HPV testing in these younger women
although the decision to use it has to be weighed against
the possibility that these higher-risk women may not get
the screening they need in the future.
While we did not observe an increase in alpha 3/4/15
genotypes in cervical specimens with age as observed in
other studies (29;30), the prevalence of these HPV geno-
types remained relatively unchanged with increasing age.
As a consequence, the proportion of alpha 3/4/15 geno-
types in the cervical specimens among any HPV infections
increased significantly with age so that the prevalence of
alpha 5/6/7/9/11 and alpha 3/4/15 genotypes were approxi-
mately the same in women 50 and older. To our surprise,



































































































































50-65 y.oD. Alpha 3/4/15C. Alpha 5/6/7/9/11
A. Any HPV B. Any Carcinogenic HPV
Figure 1 The age group-specific prevalence of any (A), any carcinogenic (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68)
(B), any alpha 5/6/7/9/11 (HPV16, 18, 26, 31, 33, 35, 39, 45, 51-56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82, and 82v) (C), and alpha 3/4/15
(HPV 61, 62, 71, 72, 81, 83, 84, and 89) (D) human papillomavirus (HPV) types as detected in clinician-collected cervical specimens and
self-collected cervicovaginal specimens. Age groups were 26-29 (white bars), 30-39 (light gray bars) , 40-49 (medium gray bars), and 50-65
(black bars) years old (y.o.).
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was similar to that of the cervix, with higher prevalence of
alpha 5/6/7/9/11 genotypes than alpha 3/4/15 genotypes in
young women rather than the preponderance of alpha 3/4/
15 genotypes at all ages. The differences in this study versus
other studies could be due to the relative small sample size
in this study or unmeasured differences in sexual behaviors.
Another possibility is that self-collection device used in this
study did a better job of sampling the cervix, making the
self-collected specimens more representative of the cervical
milieu of HPV genotypes than observed in other studies.
We note that the one of our limitations for this study is
that we used non-FDA approved HPV test, self-collection
device, and transport medium. Linear Array, the HPV test
used in this study, is one of the standard methods for
HPV genotyping [40] and has been shown to correlate well
with Hybrid Capture 2 [24,41] and cobas4800 [42], two
FDA-approved tests. There is no collection device, includ-
ing tampons and collection brushes and brooms, which is
FDA approved for self-collection. Finally, mouthwash has
been used for genetic (DNA) testing for epidemiologic
studies, including those that send specimens through the
mail [43]. Here, we applied it to HPV DNA rather than
host genomic DNA. Nevertheless, the results of this ana-
lysis should be considered in relative rather than absolute
terms since it is possible that that the methods in this
study led to false positive and/or false negative results.
Conclusions
Our data illustrated how self-collected specimens can
result in significantly higher point prevalence of HPV
(lower specificity), including carcinogenic HPV, than a
cervical specimen. The point prevalence of HPV using
self-collected specimens in this study was comparable
to what was recently reported [44] in a nationally
representative HPV survey using cervicovaginal lavages
tested with the same HPV genotyping assay. On one
hand, the self-collected cervicovaginal specimens,
with the higher point prevalence, may be more repre-
sentative of the total lower female genital tract burden
to HPV than samples taken only from the cervix. Self-
collection, despite the increased detection of carcino-
genic HPV, is not as sensitive as a clinician-collection
for detecting prevalent cervical precancer or cancer
[6]. However, it is unknown whether added detection
of vaginal carcinogenic HPV not found at the cervix is
in anyway associated with future risk of the cervical or
lower genital tract HPV-related cancer.
Additional file
Additional file 1: Table S1. The prevalence of 37 HPV genotypes in
clinician-collected and self-collected specimens. Bold type indicates
statistically greater prevalence of that type as determined using an exact
version of the McNemar’s tests.
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